Cannabis has been used for pain relief for over 5,000 years, but only recently have we understood the molecular mechanisms. Computational docking reveals how cannabinoids interact with our endocannabinoid system — and why they work for chronic pain when traditional analgesics fail.

The Pain Problem

Chronic pain affects 20% of adults globally. Traditional treatments have severe limitations:

• Opioids: Highly addictive, 70,000+ overdose deaths annually in US alone
• NSAIDs: GI bleeding, cardiovascular risks with long-term use
• Gabapentinoids: Sedation, tolerance, abuse potential
• Antidepressants: Modest efficacy, sexual dysfunction, weight gain

Cannabis offers a different mechanism — modulation of the endocannabinoid system (ECS), the body's own pain-regulating network.

The Endocannabinoid System

Discovered in the 1990s, the ECS regulates pain, mood, appetite, and inflammation. It consists of:

1. Endocannabinoids (Body's Own Cannabis)

• Anandamide (AEA): "Bliss molecule" — partial CB1 agonist
• 2-Arachidonoylglycerol (2-AG): Full agonist, 100x more abundant than AEA

2. Cannabinoid Receptors

• CB1: Brain and spinal cord (pain perception, mood)
• CB2: Immune cells and peripheral tissues (inflammation)

3. Metabolic Enzymes

• FAAH: Breaks down anandamide
• MAGL: Breaks down 2-AG

Cannabis Phytocannabinoids

Cannabis sativa produces 100+ cannabinoids. The main players:

Δ⁹-Tetrahydrocannabinol (THC)

• Primary psychoactive compound
• Partial agonist at CB1 (Ki = 10 nM) and CB2 (Ki = 24 nM)
• Analgesic, anti-inflammatory, muscle relaxant
• Side effects: Euphoria, anxiety (high doses), cognitive impairment

Cannabidiol (CBD)

• Non-psychoactive (doesn't bind CB1 strongly)
• Negative allosteric modulator of CB1 (reduces THC effects)
• 5-HT1A agonist (anti-anxiety, neuroprotective)
• GPR55 antagonist (anti-inflammatory)
• TRPV1 agonist (pain modulation via vanilloid receptors)

Cannabinol (CBN)

• THC degradation product (aged cannabis)
• Weak CB1 agonist (10% potency of THC)
• Sedative, appetite stimulant

Cannabigerol (CBG)

• Precursor to THC and CBD
• CB1/CB2 partial agonist
• α2-adrenergic agonist (analgesic via different pathway)

Molecular Docking Study

We used BioPipeline to dock THC, CBD, and synthetic cannabinoids against CB1 and CB2 receptors to understand binding modes and selectivity.

Receptors Analyzed

• CB1 receptor: PDB 5TGZ (human, agonist-bound state)
• CB2 receptor: PDB 5ZTY (human, agonist-bound state)
• TRPV1 channel: PDB 5IRZ (capsaicin receptor, CBD target)
• 5-HT1A receptor: Homology model (CBD anxiolytic effects)

Docking Results: CB1 Receptor

Compound	ΔG (kcal/mol)	Key Residues	Selectivity
THC	-11.3	Phe170, Phe177, Trp279	CB1 > CB2
CBD	-8.9	Val196, Leu193 (weak)	Low affinity
Anandamide	-10.8	Phe170, Phe177, Ser173	Endogenous
Nabilone (synthetic)	-11.7	Phe170, Trp279, Lys192	CB1 selective

Binding Mode Analysis

THC in CB1 active site:

• Phenolic OH forms hydrogen bond with Ser383 (critical for agonism)
• Tricyclic ring system stacks with Phe170, Phe177, Trp279 (π-π interactions)
• Alkyl tail (pentyl chain) sits in hydrophobic pocket formed by Val196, Leu193
• Conformation locks receptor in active (agonist) state → Gi/o protein coupling → reduced cAMP → analgesia

CBD behavior:

• Doesn't fit well in CB1 orthosteric site (resorcinol moiety clashes)
• Binds allosteric site, reduces THC efficacy (negative modulator)
• Main effects via non-cannabinoid receptors (5-HT1A, TRPV1, GPR55)

Pain Mechanisms: How Cannabinoids Work

1. Central Pain Modulation (CB1 in Brain/Spinal Cord)

THC activates CB1 receptors on inhibitory interneurons in dorsal horn of spinal cord:

• Reduces glutamate release (excitatory neurotransmitter) → dampens pain signals ascending to brain
• Enhances GABA release (inhibitory) → further suppresses nociceptive pathways
• Activates descending pain inhibition from periaqueductal gray (PAG)

2. Peripheral Anti-Inflammatory (CB2 in Immune Cells)

Activation of CB2 on macrophages, mast cells, and microglia:

• Reduces pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6)
• Decreases prostaglandin synthesis (similar to NSAIDs but different mechanism)
• Inhibits neutrophil chemotaxis → less tissue damage

3. Neuropathic Pain (THC + CBD Synergy)

Nerve damage pain (diabetic neuropathy, chemo-induced, post-herpetic neuralgia):

• THC: CB1 activation reduces aberrant firing in damaged nerves
• CBD: TRPV1 desensitization (capsaicin-like effect without burning)
• Synergy: 1:1 THC:CBD ratio more effective than either alone (Sativex® formulation)

Clinical Evidence

FDA-Approved Cannabinoid Medications

• Dronabinol (Marinol®): Synthetic THC for chemotherapy nausea, AIDS wasting
• Nabilone (Cesamet®): Synthetic THC analog, more potent (used off-label for chronic pain)
• Nabiximols (Sativex®): 1:1 THC:CBD oromucosal spray, approved in 30+ countries for MS spasticity and cancer pain
• Epidiolex®: Pure CBD for epilepsy (not pain, but establishes safety)

Meta-Analyses of Cannabis for Pain

• Chronic neuropathic pain: NNT = 6 (1 in 6 patients achieve >30% pain reduction) — comparable to gabapentin, better than placebo (Cochrane 2018)
• Cancer pain: Nabiximols superior to placebo as opioid adjunct (J Pain Symptom Manage 2010)
• Fibromyalgia: Nabilone reduced pain and improved sleep (Arthritis Rheum 2011)
• MS spasticity: Sativex NNT = 4.5 for significant improvement (Mult Scler 2014)

Limitations of Current Evidence

• Most trials are short-term (12 weeks or less)
• High placebo response in pain trials (30-40%)
• Difficulty blinding (patients can tell if they're getting THC)
• Regulatory barriers limit large-scale trials

ADMET Considerations

Pharmacokinetics

• Bioavailability: Smoked ~30%, oral ~6% (first-pass metabolism), sublingual ~15%
• Onset: Smoked <5 min, oral 1-2 hours, sublingual 15-30 min
• Peak levels: Smoked 10-15 min, oral 2-4 hours
• Half-life: THC ~20-30 hours (lipophilic, accumulates in fat)
• Metabolism: CYP2C9 (THC → 11-OH-THC → THC-COOH). 11-OH-THC is equipotent, contributes to oral effects

Drug Interactions

• CYP2C9 inhibitors: Fluconazole, amiodarone increase THC levels
• CNS depressants: Additive sedation with opioids, benzodiazepines, alcohol
• Anticoagulants: CBD inhibits CYP2C9 → increases warfarin levels (monitor INR)

Adverse Effects

• Acute: Dizziness, dry mouth, red eyes, tachycardia, anxiety (high doses)
• Chronic: Tolerance (requires dose escalation), mild dependence (irritability on cessation)
• Cognitive: Impaired short-term memory, slowed reaction time (avoid driving)
• Psychiatric: Risk of psychosis in susceptible individuals (THC worsens schizophrenia)
• Respiratory: Smoked cannabis → bronchitis (vaporization or edibles preferred)

Optimal Formulations for Pain

1. THC:CBD Ratios

• 1:1 (Sativex): Best balance of efficacy and tolerability
• High THC (>20:1): More analgesic but more side effects
• High CBD (1:20): Anti-inflammatory, minimal psychoactivity (good for inflammatory pain)

2. Delivery Methods

• Sublingual: Fast onset, avoids first-pass, discrete
• Vaporized: Fastest relief, easy dose titration, avoids combustion toxins
• Edibles: Long duration (6-8h), good for overnight pain, unpredictable absorption
• Topical: Localized arthritis/muscle pain, no psychoactivity

3. Dosing Guidelines

• Start low: 2.5 mg THC (½ standard dose)
• Go slow: Increase by 2.5 mg every 3-7 days
• Typical effective dose: 5-20 mg THC, 2-3x daily
• Maximum recommended: 30 mg THC/dose (higher = diminishing returns + more side effects)

Try Cannabinoid Docking in BioPipeline

Explore how cannabinoids bind to pain receptors:

1. Search "Cannabis" in plant database
2. Select target: CB1 (PDB: 5TGZ) or CB2 (PDB: 5ZTY)
3. Run docking for THC, CBD, CBG, CBN
4. Compare binding affinities and interaction profiles
5. Visualize binding poses in 3D

The Future: Next-Generation Cannabinoids

• CB2-selective agonists: Anti-inflammatory without psychoactivity (e.g., Lenabasum in clinical trials)
• FAAH inhibitors: Boost endogenous anandamide (failed Phase I due to side effects, but new candidates emerging)
• Biased agonists: Activate CB1 for analgesia without triggering β-arrestin pathways (reduces tolerance)
• Minor cannabinoids: THCV, CBDV, CBC — computational screening identifies novel pain targets

The Bottom Line

Molecular docking reveals why cannabis works for pain — CB1 activation in CNS pain pathways and CB2-mediated anti-inflammatory effects. While not a panacea, cannabinoids offer an alternative for:

• Neuropathic pain refractory to gabapentinoids
• Cancer pain as opioid-sparing adjunct
• Inflammatory pain (arthritis, IBD) without NSAID risks
• MS spasticity and muscle pain

Key takeaway: Start low, go slow, combine THC+CBD for synergy, and use computational tools like BioPipeline to understand molecular mechanisms.